Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Jul 27, 2014; 6(7): 496-503
Published online Jul 27, 2014. doi: 10.4254/wjh.v6.i7.496
Published online Jul 27, 2014. doi: 10.4254/wjh.v6.i7.496
Figure 4 Contrast-enhanced ultrasound of liver parenchyma in controls, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
A: Peak (%); B: TTP (s); C: RBV (cm3); D: RBF (cm3/s); Peak (%): Maximum signal intensity (SI) reached during SonoVue® bolus injection; TTP (s): Time to peak; RBV (cm3): Regional blood volume; RBF (cm3/s): Regional blood flow; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.
- Citation: Cocciolillo S, Parruti G, Marzio L. CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. World J Hepatol 2014; 6(7): 496-503
- URL: https://www.wjgnet.com/1948-5182/full/v6/i7/496.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i7.496